ERBB2 and neoplasm: A Ki-67 value of ≥15% was revealed to be significant in its ability to distinguish between the HER-2-negative luminal A and B1 tumor subtypes, with a higher DFS rate in patients with the luminal A subtype compared with the luminal B1 subtype (P=0.036).